How many drugs treat Chronic type B viral hepatitis?

Drug Landscape tracks 10 marketed treatments for Chronic type B viral hepatitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-type-b-viral-hepatitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic type B viral hepatitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic type B viral hepatitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic type B viral hepatitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Baraclude	ENTECAVIR	Bristol-Myers Squibb	entecavir		2005-01-01
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
Pegasys	PEGINTERFERON ALFA-2A	Hoffman-La Roche		Interferon alpha/beta receptor	2002-01-01
Epivir	LAMIVUDINE	GSK	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Deoxycytidine kinase	1995-01-01
Intron A	INTERFERON ALFA-2B	Merck & Co.	Interferon alpha		1986-01-01
Pegasys	Pegasys	Zealand University Hospital		Interferon alpha/beta receptor
Baraclude	Baraclude	Bristol-Myers Squibb		Capsid protein, Protein P, Protein P
Viread	Viread	Replicor Inc.		Gag-Pol polyprotein, Reverse transcriptase/RNaseH
Hepsera	Hepsera	Gilead Sciences		DNA polymerase subunit gamma-1, Capsid protein, Protein P
Peginterferon	Peginterferon	Ziv Hospital	Interferon beta [EPC]	Interferon alpha/beta receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Chronic type B viral hepatitis
Bristol-Myers Squibb · 2 drugs in Chronic type B viral hepatitis
Gilead Sciences · 2 drugs in Chronic type B viral hepatitis
Ziv Hospital · 2 drugs in Chronic type B viral hepatitis
Hoffman-La Roche · 1 drug in Chronic type B viral hepatitis
Merck & Co. · 1 drug in Chronic type B viral hepatitis
Replicor Inc. · 1 drug in Chronic type B viral hepatitis
GSK · 1 drug in Chronic type B viral hepatitis
Zealand University Hospital · 1 drug in Chronic type B viral hepatitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic type B viral hepatitis:

Cite this brief

Drug Landscape (2026). Chronic type B viral hepatitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-type-b-viral-hepatitis. Accessed 2026-06-10.

Chronic type B viral hepatitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing